Main menu

Pages

Scientists develop two drugs that can prevent corona infection and stop the spread of the virus


Scientists in the Australian state of Queensland have developed two drugs that can prevent infection with the Corona virus, but also prevent its spread among people who are already infected, and experts at QIMR Berghofer Institute for Medical Research have identified peptide-based drugs and believe that they can change the treatment of the Corona virus.


According to the British newspaper "Daily Mail", these drugs can be available within 18 months if the experiments are successful, and the drugs target how human cells interact with the virus, instead of developing antibodies against the virus through a vaccine.


The journal Nature Cell Discovery included the results Monday, indicating a shift in planning for the next phase of coronavirus treatment.


Professor Sudha Rao, senior researcher at QIMR Berghofer, said that the peptides were "an early preventive drug", working together in two important roles, the first drug works by preventing the entry of the virus because it works effectively as a lock on human cells and the second drug, if it enters the virus, it It prevents the virus from reproducing. "


The researchers discovered a new way for the virus to enter cells, through AC2 receptors, which they believe will be necessary for the further development of drugs to prevent corona virus.


Professor Rao explained that, "Once the virus enters it, it can use the cellular mechanism in human cells for reproduction, but the first drug acts like a mantle around the human cell, thus preventing the virus from entering through the AC2 receptors."


And she continued, "If the virus enters, the second drug is present specifically to prevent the virus from reproducing."


The peptides will be effective against all virus mutations because cells operate in the same way, contrary to the need for constant updates of vaccines.


The scientists said the early results are "very promising" and they hope to conduct clinical trials on humans within the coming months.


QIMR Berghofer is also working with a group of European scientists, and believes the drug rollout will be rapid due to the availability of the peptides and the ease of storage and transportation at room temperature.

reactions

Comments